Related Experiment Video
Updated: May 4, 2026
07:34
Author Spotlight: Establishing a Reliable Distal MCA Occlusion Model in Mice for Stroke Research
Published on: December 15, 2023
3.2K
Targeting microglial activation in stroke therapy: pharmacological tools and gender effects
1Dept. of Neurology, University of California San Francisco; and Neurology Service, San Francisco Veterans Affairs Medical Center, 4150 Clement St, San Francisco, CA 94121, USA. raymond.swanson@ucsf.edu.
Current Medicinal Chemistry
|December 31, 2013
Summary
Targeting microglial activation pathways offers a therapeutic window for ischemic stroke. Suppressing these immune responses may reduce brain damage and improve outcomes.
Area of Science:
- Neuroscience
- Immunology
- Pharmacology
Background:
- Ischemic stroke involves reduced blood flow to the brain, triggering a detrimental microglial immune response.
- Activated microglia release cytotoxic factors, exacerbating neuronal damage and recruiting peripheral immune cells.
- The development of microglial activation presents a therapeutic window for intervention.
Purpose of the Study:
- To review preclinical studies on drugs targeting microglial activation post-stroke.
- To explore therapeutic strategies aimed at suppressing detrimental neuroinflammation.
- To examine the influence of sex differences on CNS inflammatory responses and therapeutic efficacy.
Main Methods:
- Review of preclinical studies investigating drug interventions in ischemic stroke models.
- Analysis of drugs targeting global gene expression in microglial activation.
- Inclusion of research on sex differences in central nervous system (CNS) inflammation.
Main Results:
- Several drug classes, including HDAC inhibitors and minocycline, show potential in suppressing microglial activation.
- Targeting microglial pathways can mitigate secondary brain injury following ischemic events.
- Emerging evidence highlights significant sex-based variations in neuroinflammatory responses.
Conclusions:
- Modulating microglial activation is a promising therapeutic strategy for ischemic stroke.
- Drug development should consider sex differences to optimize treatment efficacy.
- Further research is needed to translate these preclinical findings into clinical practice.
